Matica Bio & Mongoose Bio Team Up To Advance TCR-T Cell Therapy

Texas-based viral vector CDMO, Matica Biotechnology, has teamed up with Mongoose Bio, a pioneering biotech firm, to drive forward the development and production of lentivirus for Mongoose Bio’s TCR-T cell therapy pipeline targeting cancer.

As part of this collaboration, Matica Bio will handle all aspects of process development, analytical method creation, and the manufacturing of non-clinical and clinical viral vector materials. The lentivirus vector will serve as a critical component in producing the final TCR-T cell therapy product.

This partnership underscores Matica Bio’s influence as a leading CDMO in Texas, reinforcing its reputation in the local bio-ecosystem. By establishing strong collaborations with local biotech innovators, hospitals, and research institutions, Matica Bio aims to solidify its position as a preferred partner within Texas's rapidly expanding biocluster.

"We are honored to collaborate with a team that shares our dedication to improving patient outcomes and advancing the frontiers of cancer treatment," stated Paul Kim, CEO of Matica Bio.

Neil Warma, President and CEO of Mongoose Bio, mentioned, “We are pleased to be working with Matica Bio on viral vector manufacturing to advance our novel TCR-T therapies into the clinic. Our novel technology is based on over 20 years of research and development expertise and an extensive patent portfolio. It is particularly meaningful to collaborate with leading CDMOs, like Matica Bio, hospitals, and development companies in our goal of conducting global clinical trials to bring our cancer treatments to patients worldwide.”